Corcept Therapeutics CFO Mokari sells $3.5m in shares

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc. (NASDAQ:CORT), sold company shares worth approximately $3.51 million on July 15, 2026. These transactions followed the acquisition of shares through the exercise of stock options on the same day.

Concurrently with the sales, Mokari acquired 40,000 shares of common stock through the exercise of fully exercisable stock options. These shares were acquired at prices between $19.26 and $23.06 per share, totaling approximately $862,234.

Following these transactions, Mokari directly owns 16,130 shares of Corcept Therapeutics common stock. This total includes shares underlying unvested restricted stock awards: 200 shares granted on September 2, 2025; 178 shares granted on December 1, 2025; 397 shares granted on March 2, 2026; and 634 shares granted on June 1, 2026. These restricted stock awards are scheduled to vest one year from their respective grant dates, provided certain requirements are met by the reporting person.

In other recent news, Corcept Therapeutics has made significant strides with its drug developments and financial outlook. The company resubmitted its New Drug Application for relacorilant, targeting Cushing’s syndrome, to the U.S. Food and Drug Administration. This resubmission includes additional analyses as requested by the FDA, with an expected six-month review period. Meanwhile, Corcept presented promising survival data from its Phase 3 ROSELLA trial at the American Society of Clinical Oncology annual meeting. The trial demonstrated that patients receiving the combination of Lifyorli and nab-paclitaxel experienced a 35% reduction in the risk of death compared to those on nab-paclitaxel alone.

Additionally, H.C. Wainwright reiterated a Buy rating for Corcept, highlighting the positive data from the ASCO meeting. The firm also raised its stock price target to $75 from $65, following Corcept’s recent financial results. The company reported first-quarter revenues of approximately $165 million, which fell short of the consensus estimate of $186 million. These developments underscore the ongoing progress and challenges faced by Corcept Therapeutics in its drug development and financial performance.